IQVIA’s Breakthrough Natural Language Processing Platform Receives 2019 Fierce Innovation Award
January 30 2020 - 8:00AM
Business Wire
IQVIA™ (NYSE: IQV) announced today that its Linguamatics Natural
Language Processing (NLP) platform has been selected as the winner
in Questex’s 2019 Fierce Innovation Awards — LifeSciences Edition
in the Data Analytics/Business Intelligence category. The Fierce
Innovation Awards is a peer-reviewed awards program from the
publisher of FierceBiotech and FiercePharma and recognizes IQVIA
Linguamatics NLP platform as an industry-leading product.
“We are honored to receive this award, which acknowledges our
commitment to developing technologies that use AI/ML to improve
health,” said Ben Hughes, senior vice president, Artificial
Intelligence & Real World Data at IQVIA. “Our teams are
leveraging natural language processing, artificial intelligence and
machine learning to drive healthcare breakthroughs from early
discovery to clinical research, through commercialization and
beyond.”
The IQVIA Linguamatics NLP platform uniquely combines
flexibility, scale and data transformation to analyze petabytes of
unstructured data. The NLP platform supports the entire spectrum of
life science and healthcare applications – ranging from gene
mapping and target identification to health economics and outcomes
research, market intelligence activities, and patient care and
outcomes. The NLP text-mining is part of IQVIA’s artificial
intelligence and machine learning software portfolio, helping
clients seeking to speed up drug development and improve patient
outcomes by breaking down data silos, boosting innovation, and
generating new actionable insights.
The Fierce Innovation Awards highlight companies that
demonstrate innovative solutions, technologies and services that
have the potential to make the greatest impact for biotech and
pharma companies. Winners and finalists’ applications were reviewed
by an exclusive panel of executives from major biotech and pharma
companies. All applications were evaluated based on effectiveness,
technical innovation, competitive advantage, financial impact and
true innovation.
Winners were announced in the 2019 Innovation Report published
by FierceHealthcare in December 2019.
For more information on IQVIA AI and ML solutions, please visit
https://www.iqvia.com/solutions/innovative-models/artificial-intelligence-and-machine-learning.
About Questex
At Questex, we are passionate about driving business outcomes.
We connect buyers and sellers and help both achieve their goals. We
are online, on devices and live with experiential engagements. We
understand the buyer’s behavior and evolving needs and connect them
with the seller through continual touchpoints. From discovery
through purchase and purchase through advocacy, we supply unmatched
access, insight, engagement and turnkey solutions all in one
place.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With approximately
65,000 employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200130005428/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732 Andrew Markwick, IQVIA
Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024